MA24237A1 - Sulfonamides et leur utilisation. - Google Patents

Sulfonamides et leur utilisation.

Info

Publication number
MA24237A1
MA24237A1 MA24694A MA24694A MA24237A1 MA 24237 A1 MA24237 A1 MA 24237A1 MA 24694 A MA24694 A MA 24694A MA 24694 A MA24694 A MA 24694A MA 24237 A1 MA24237 A1 MA 24237A1
Authority
MA
Morocco
Prior art keywords
sulfonamides
Prior art date
Application number
MA24694A
Other languages
English (en)
Inventor
Riemer Claus
Sleight Andrew
Michael Boes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24237(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA24237A1 publication Critical patent/MA24237A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
MA24694A 1996-06-28 1997-06-27 Sulfonamides et leur utilisation. MA24237A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96110462 1996-06-28
EP97105363 1997-04-01

Publications (1)

Publication Number Publication Date
MA24237A1 true MA24237A1 (fr) 1997-12-31

Family

ID=26142037

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24694A MA24237A1 (fr) 1996-06-28 1997-06-27 Sulfonamides et leur utilisation.

Country Status (29)

Country Link
US (4) US5939451A (fr)
EP (1) EP0815861B1 (fr)
JP (1) JP3032176B2 (fr)
KR (1) KR100260480B1 (fr)
CN (1) CN1086578C (fr)
AR (2) AR007617A1 (fr)
AT (1) ATE205714T1 (fr)
AU (1) AU694696B2 (fr)
BR (1) BR9703788A (fr)
CA (1) CA2209018C (fr)
CO (1) CO4900073A1 (fr)
CZ (1) CZ9702002A3 (fr)
DE (1) DE59704640D1 (fr)
DK (1) DK0815861T3 (fr)
ES (1) ES2163071T3 (fr)
HK (1) HK1007865A1 (fr)
HR (1) HRP970349B1 (fr)
HU (1) HUP9701096A3 (fr)
IL (1) IL121141A (fr)
MA (1) MA24237A1 (fr)
MX (1) MX9704817A (fr)
NO (1) NO972983L (fr)
NZ (1) NZ328146A (fr)
PL (1) PL320822A1 (fr)
PT (1) PT815861E (fr)
RU (1) RU2192257C2 (fr)
SG (1) SG77139A1 (fr)
TR (1) TR199700550A2 (fr)
YU (1) YU27697A (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) * 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6686374B1 (en) * 1999-08-12 2004-02-03 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
DE10053813A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung von Sulfonamiden
ITBO20010271A1 (it) * 2001-05-08 2002-11-08 Giuseppe Cannazza Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl
CA2443724C (fr) 2001-05-11 2009-11-03 Patrizia Caldirola Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
NZ529032A (en) 2001-06-11 2007-04-27 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
AU2003213184A1 (en) * 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Pyridyl sulfone derivatives as 5-ht receptor antagonists
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897876A3 (fr) 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
US6989399B2 (en) 2002-08-01 2006-01-24 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-alkanol derivatives
US7319111B2 (en) 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
ES2222829B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222830B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
JP2007514731A (ja) * 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
BRPI0516749B8 (pt) * 2004-09-30 2021-05-25 Hoffmann La Roche composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos
EP1676841A1 (fr) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments
GB0518667D0 (en) 2005-09-13 2005-10-19 Univ Reading The Method
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
WO2008114831A1 (fr) * 2007-03-20 2008-09-25 National University Corporation Okayama University Agent antibactérien comprenant un groupe sulfamide
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
CN101591327B (zh) * 2008-05-26 2012-07-25 华东理工大学 苯烷酰胺类化合物及其用途
US9029545B2 (en) * 2009-12-18 2015-05-12 Glaxosmithkline Intellectual Property Limited Thienopyridine NOX2 inhibitors
US20150291517A1 (en) * 2012-11-28 2015-10-15 Martijn Fiers Benzenesulfonamide compounds for somatic embryogenesis in plants
WO2016090317A1 (fr) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Dérivés de sulfonamide, compositions et procédés d'utilisation dans le traitement de maladies neurodégénératives
EP3412652A1 (fr) 2017-06-06 2018-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs de rac1 comme anticancéreux
EP3412651A1 (fr) * 2017-06-06 2018-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs de rac1 contre asthme
CN115703722A (zh) * 2021-08-03 2023-02-17 江苏国泰超威新材料有限公司 一种n,n-二甲基三氟甲基磺酰胺的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2192490A (en) * 1936-03-21 1940-03-05 Hoffmann La Roche Derivatives of 4-aminobenzenesulphonamides and process for the manufacture of same
NL127990C (fr) * 1962-12-29
FR1383287A (fr) * 1962-12-29 1964-12-24 Chugai Pharmaceutical Co Ltd Procédé de production de 4-sulfanilamidopyrimidines
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
JPH04202173A (ja) * 1990-11-30 1992-07-22 Zeria Pharmaceut Co Ltd スルホンアミド誘導体及びそれを含有する５―リポキシゲナーゼ阻害剤
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体

Also Published As

Publication number Publication date
HUP9701096A2 (hu) 1999-02-01
AU2841697A (en) 1998-01-22
YU27697A (sh) 2000-03-21
EP0815861A1 (fr) 1998-01-07
KR100260480B1 (ko) 2000-07-01
MX9704817A (es) 1997-12-31
US5939451A (en) 1999-08-17
EP0815861B1 (fr) 2001-09-19
US6030976A (en) 2000-02-29
TR199700550A2 (xx) 1998-01-21
DE59704640D1 (de) 2001-10-25
HRP970349A2 (en) 1998-04-30
DK0815861T3 (da) 2002-01-21
ES2163071T3 (es) 2002-01-16
BR9703788A (pt) 1998-11-17
PL320822A1 (en) 1998-01-05
US5998665A (en) 1999-12-07
CA2209018A1 (fr) 1997-12-28
NO972983D0 (no) 1997-06-26
ATE205714T1 (de) 2001-10-15
CA2209018C (fr) 2002-10-01
IL121141A (en) 2001-12-23
CN1170574A (zh) 1998-01-21
CN1086578C (zh) 2002-06-26
IL121141A0 (en) 1997-11-20
JPH1067734A (ja) 1998-03-10
AR007617A1 (es) 1999-11-10
NZ328146A (en) 1999-10-28
HUP9701096A3 (en) 2000-08-28
SG77139A1 (en) 2000-12-19
CO4900073A1 (es) 2000-03-27
PT815861E (pt) 2002-02-28
AU694696B2 (en) 1998-07-23
US5932599A (en) 1999-08-03
NO972983L (no) 1997-12-29
KR19980079284A (ko) 1998-11-25
HK1007865A1 (en) 1999-04-30
AR045878A2 (es) 2005-11-16
HU9701096D0 (en) 1997-08-28
CZ9702002A3 (cs) 1998-01-14
RU2192257C2 (ru) 2002-11-10
HRP970349B1 (en) 2002-06-30
JP3032176B2 (ja) 2000-04-10

Similar Documents

Publication Publication Date Title
MA24237A1 (fr) Sulfonamides et leur utilisation.
MA24273A1 (fr) (4-arylthiazol-2yl) sulfonamides et leur utilisation
MA25688A1 (fr) 2-thio-3, 5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation.
NO983462D0 (no) Isoleringsverkt°y
NO985766D0 (no) B°lgeenergiomformer
NO975768D0 (no) Tilkoblings-, skille- og koblingslist
NO990552D0 (no) Innrettingsverkt°y
DE69714146T2 (de) Polyether modifizierte Fluoralkylsiloxane
BR9708248A (pt) Benzotiofenos formulações contendo os mesmos e metódos
BR9707657A (pt) Benzotiofenos formulações contendo os mesmos e métodos
FR2702930B1 (fr) Iodophores perfectionnes, leur production et leur utilisation.
DE69709173T2 (de) Belastungswalzenanordnüng.
DE29619891U1 (de) Siebrechen
NO992357D0 (no) B°yekonstruksjon
FR2722198B1 (fr) 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
ES1036598Y (es) Capazo-cuna.
DE29612712U1 (de) Spielekoffer
ES1033200Y (es) Linterna - caramelo.
DE29609091U1 (de) Funktions-Karte
ES1035219Y (es) Chincheta-clip.
ES1034158Y (es) Arsonvalizador.
ES1033500Y (es) Caja-expositor.
KR980002925U (ko) 합·연사 장치
ES1033877Y (es) Nueva caperuza-precinto.
BR7603019U (pt) Quebra-cabeças